aTyr Pharma(US:LIFE)2026-03-05 21:03Financial Position - aTyr Pharma ended 2025 with a cash position of $80.9 million, including cash, cash equivalents, restricted cash, and investments[2]. - Total assets decreased from $96,830 million in 2024 to $93,003 million in 2025, a decline of approximately 2.9%[17]. - Cash, cash equivalents, and restricted cash increased from $75,076 million in 2024 to $80,922 million in 2025, an increase of about 7.7%[17]. - Total stockholders' equity decreased from $69,832 million in 2024 to $67,288 million in 2025, a decrease of approximately 3.6%[17]. - Long-term operating lease liability decreased from $11,144 million in 2024 to $10,308 million in 2025, a reduction of about 7.5%[17]. - Current portion of financing lease liability increased from $541 million in 2024 to $630 million in 2025, an increase of approximately 16.4%[17]. - Other receivables decreased significantly from $1,736 million in 2024 to $873 million in 2025, a decline of about 49.7%[17]. - Property and equipment, net decreased from $4,850 million in 2024 to $4,263 million in 2025, a decrease of approximately 12.1%[17]. - Prepaid expenses and other assets decreased from $8,159 million in 2024 to $825 million in 2025, a decline of about 89.9%[17]. - Current portion of operating lease liability increased from $711 million in 2024 to $836 million in 2025, an increase of approximately 17.6%[17]. - Total liabilities and stockholders' equity remained unchanged at $93,003 million in 2025 compared to 2024[17]. Revenue and Expenses - The company reported a consolidated net loss of $74.1 million for the year ended 2025, compared to a net loss of $64.0 million for the year ended 2024[15]. - The total revenues for the year ended 2025 were $190,000, a decrease from $235,000 in 2024[15]. - Research and development expenses for the year ended 2025 were $60.2 million, primarily for the Phase 3 EFZO-FIT™ and Phase 2 EFZO-CONNECT™ studies[12]. - General and administrative expenses for the year ended 2025 were $17.6 million[12]. Clinical Studies - The Phase 3 EFZO-FIT™ study evaluated 268 patients with symptomatic pulmonary sarcoidosis, but did not meet its primary endpoint of reducing mean daily oral corticosteroid dose at week 48[5][6]. - Clinical benefits were observed for the 5.0 mg/kg efzofitimod group across multiple efficacy parameters, including a significant improvement in the King's Sarcoidosis Questionnaire-Lung score (p=0.0479)[6]. - The Phase 2 EFZO-CONNECT™ study is on track to complete enrollment in the first half of 2026, targeting patients with systemic sclerosis-related interstitial lung disease[8]. - aTyr Pharma plans to meet with the FDA in mid-April 2026 to discuss the Phase 3 EFZO-FIT™ study results and the future of efzofitimod in pulmonary sarcoidosis[5]. - The company presented promising interim data for ATYR0101, demonstrating a favorable pharmacokinetic and immunogenicity profile[8].